Home > Healthcare & Medical Devices > Tubeless Insulin Pump Market

Tubeless Insulin Pump Market Size By End-use (Homecare, Hospitals & Clinics), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Australia, RoW), Application Potential, Competitive Market Share & Forecast, 2022 – 2030

  • Report ID: GMI2032
  • Published Date: May 2022
  • Report Format: PDF

Industry Overview

Tubeless Insulin Pump Market was valued at around USD 1.1 billion in 2021 and is estimated to witness a CAGR of 21.1% from 2022 to 2030 driven by the surging incidence and prevalence rates of diabetes. The increasing disease burden along with incremental healthcare expenses associated with diabetes is projected to impel the business growth during the analysis period.

Get more details on this report - Request Free Sample PDF

For instance, according to the International Diabetes Foundation’s Diabetes Atlas, in 2021, diabetes accounted for approximately 6.7 million deaths in 2021, equating to 1 every 5 seconds. In addition to this, the heightened healthcare expenditure coupled with surged demand for advanced tubeless insulin pump that are discreet & user friendly are predicted to propel the tubeless insulin pump market.

Tubeless insulin pump refers to a wireless insulin management system that is connected to the remote using Bluetooth connectivity and offers continuous insulin delivery, further eliminating the need for multiple daily injections.

However, high long-term costs associated with tubeless insulin pump and stringent government regulations may negatively impact the business growth. In emerging economies, the high long-term costs concerned with diabetes treatment & management using tubeless insulin pump may affect the adoption rate of these devices. Poor reimbursement scenario in some countries impact its affordability for patients.

Furthermore, the U.S. FDA evaluates the research & development, authorization, and post-approval surveillance concerned with medical devices, including tubeless insulin pump. Tubeless insulin devices are categorized as Class II medical devices that are required to adhere to stringent regulatory approval processes & compliances. Thus, strict regulatory framework & high cost may hamper the demand for tubeless insulin pump, further hindering the industry growth.

The COVID-19 pandemic arose as a global health concern and accounted for a slightly negative impact on the tubeless insulin pump market growth, during the initial phase of the pandemic, in the first half of 2020. The pandemic has impacted the global economy by directly affecting manufacturing, disrupting the market & supply chain, and has distorted financial markets. COVID-19 had impacted the medical device industry by delaying the product adoption.

To limit the spread of the virus, national emergencies were enforced in several countries. The shutdown and movement limitations negatively affected the medical practices including diabetes management services. The World Health Organization Report, in 2020, stated that around half of the countries reported significant disruptions concerning diabetic extremity management services affecting around 49% of such practices.

In addition to this, some of the key industry players also documented slight decline in the product sales to disruption of several market operations due to the SARS-CoV-2 pandemic. Although, diabetic patients suffering from type 1 diabetes (T1D) are more vulnerable and at a high risk of COVID-19.

Therefore, certain federal agencies, regulatory bodies, and market players undertook collaborative efforts to mitigate the effects of pandemic & facilitate optimal supply of insulin delivery essentials, including tubeless insulin pump. Moreover, major players are also working with insurance companies to provide quick reimbursement. These collaborative efforts are expected to uplift the market growth in the coming years. Thus, the COVID-19 pandemic had a slightly negative impact on the tubeless insulin pump market; although, the initiatives implemented by key market players & federal agencies are anticipated to fuel the market growth in near future.

Surging prevalence of diabetes is expected to amplify the market growth

Significant increase in the number of patients suffering from diabetes is one of the prominent factors influencing the tubeless insulin pump market share. With the increasing patient population, the industry is expected to foresee tremendous growth owing to the rising preference for tubeless insulin pump due to their reliability and minimized need for multiple injections.

According to the International Diabetes Federation, the total number of diabetes patients is expected to grow by 51% from 463 million in 2019 to 700 million by 2045. The high incidence rate of diabetes is also attributable to the adoption of a sedentary lifestyle. Thus, as tubeless insulin pump offers a simplified and advanced solution to patients for diabetes management, the market is anticipated to experience unprecedented growth in the coming years.

Moreover, the pervasiveness of diabetes is higher in the geriatric population, thus, expanding the elderly pool that is further expected to present growth opportunities to the market.

Similar scenario is observed in North America with incremental diabetic population and growth rates. The IDF statistics documented that disease was responsible for 931,000 deaths in 2021. Additionally, the number of adults suffering with diabetes is projected to reach 57 million by 2030 and 63 million by 2045. The rapidly surging prevalence of diabetic patients is anticipated to accelerate the tubeless insulin pump market revenue, which will assist in regulating the blood sugar levels round the clock.

Heightened diabetes care expenditure would offer novel growth opportunities

Diabetes is amongst the major chronic conditions affecting significant population globally and inflicts substantial disease burden. The surge in the number of people suffering with diabetes have been and are expected to continue to grow. In addition to morbidity and mortality, the disease promotes significant economic burden on healthcare systems, prevalent & incident population, and households.

According to the American Diabetes Association’s (ADA) Economic Costs of Diabetes, the overall costs of diagnosed diabetes cases have increased from USD 245 billion in 2012 to USD 327 billion in 2017. These statistics represents an approximately 26% rise during the five-year period. Further, as per the IDF report, in 2021, the global diabetes accounted for around USD 966 billion dollars in health expenditure, indicating approximately 316% increase over the last 15 years.

The higher burden of diabetes in emerging economies inflicted financial strain on diabetic population and health systems. The National Centers for Biotechnology Information (NCBI) article highlighted that higher burden was profound among adults with lower educational awareness and household income in low- & middle-income countries with such disparities widening over the time.

A recent statistical analysis by the NCBI, in 2019, reported that in sub-Saharan Africa, the estimated diabetes expenditure accounts for 1.2% of cumulative gross domestic product GDP (or USD 19.5 billion), and is projected to surge to USD 35 to USD 59 billion by 2030. Thus, the significant diabetes care expenditure & incremental growth is set to drive the adoption of tubeless insulin pump to manage diabetes efficiently.

Growing adoption of tubeless insulin pump in home care settings is estimated to fuel the demand

Get more details on this report - Request Free Sample PDF

Based on end-use, the home care segment accounted for a significant market share of more than 76% in 2021 and is expected to drive the market growth during the forecast period owing to the increased adoption of these devices in home care settings. Recent advancements & incorporation of novel modalities have led to the development of novel, user-friendly devices.

The availability of these easy-to-use devices are set to expedite the tubeless insulin pump market growth. These pumps usually feature a miniaturized pod or patch that holds insulin units through the reservoir & a personal diabetes manager that helps in controlling & regulating the insulin delivery.

The integration of automated technology in these devices have increased its adoption rate, as these devices are self-manageable, enhance the user experience, & optimize patient engagement. Thus, the launch of advanced equipment that improve patient experience and are user-friendly are expected to drive the product adoption in home care settings.

High diabetic population & technological advancements in the North America region to curb the diabetes burden will promote the regional business growth


Get more details on this report - Request Free Sample PDF

The U.S. tubeless insulin pump market is projected to grow at a considerable pace to reach at around USD 3,749 million by 2030 owing to multiple factors such as high diabetes care expenditure, significant diabetic population, and the presence of facilitative initiatives to promote diabetes awareness across the country. According to the National Diabetes Statistics Report 2020, approximately 34.2 million people (10.5% of the U.S. population) were suffering from diabetes in the U.S.

The considerable diabetic population base has led to rise in the diabetes care spending. According to the NCBI article, in 2019, the U.S. diabetes care expenditure including the costs of both diagnosed & undiagnosed diabetes accounted for USD 403.9 billion annually. The surged diabetes care spending is expected to benefit the market by promoting the acceptance of advanced insulin pumps in the country.


Strategies adopted by major market players will surge the industry growth

Some of the major players operating in the tubeless insulin pump industry are Roche Diabetes Care, Insulet Corporation, Terumo Corporation, and Medtrum Technologies among others. These prominent players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue.

Recent industry developments:

  • In August 2021, Insulet Corporation announced FDA approval for using Eli Lilly’s Lyumjev injection with Insulet’s Omnipod Insulin Management System and Omnipod DASH Insulin Management System. This FDA approval helped the company to offer more clinical choices for diabetes patients to manage their glucose levels and limit post-meal elevations.
  • In March 2021, Insulet Corporation announced positive results for the first pivotal trials of its Omnipod 5 Automated Insulin Delivery System. This system is the world’s premiere tubeless, a wearable mechanism that acclimatizes insulin delivery based on glucose levels and trends. This development helped the company to highlight its robust developmental capabilities.

Tubeless insulin pump market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2030, for the following segments:

By End-use

  • Home Care
  • Hospitals & clinics
  • Others

The above information is provided for the following regions and countries:

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Australia 
  • RoW
Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Tubeless insulin pump market size was valued at USD 1.1 billion in 2021 and is anticipated to grow at a CAGR of 21.1% between 2022 and 2030 owing to the rising prevalence rates of diabetes.
The market revenue from home care was over 76% of the total industry value in 2021 and will grow on account of increasing advancements and the rising incorporation of novel modalities in home care devices.
U.S. tubeless pump insulin market value is estimated to reach USD 3,749 million until 2030 driven by multiple factors such as a significant diabetic population and the high expenditure associated with diabetes care.
Prominent companies in the tubeless insulin pump industry comprise Medtrum Technologies, Insulet Corporation, Roche Diabetes Care, Terumo Corporation, and others.

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 6
  • Tables & Figures: 63
  • Countries covered: 12
  • Pages: 100
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount